Michelle Ann Elliott

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 88:237-43. 2012
  2. ncbi request reprint Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 45:1545-9. 2004
  3. ncbi request reprint Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    M A Elliott
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 76:1154-62. 2001
  4. ncbi request reprint Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
    M A Elliott
    Hematology Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1003-8. 2006
  5. ncbi request reprint Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:571-93. 2006
  6. ncbi request reprint Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:4172-4. 2007
  7. doi request reprint Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature
    Mischelle A Elliott
    Department of Internal Medicine Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Haematol 83:365-72. 2009
  8. doi request reprint Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration
    Michelle A Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 85:43-50. 2010
  9. pmc Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
    Michelle Ann Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 95:1788-91. 2010
  10. ncbi request reprint Chronic neutrophilic leukemia: a contemporary review
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 3:210-7. 2004

Detail Information

Publications32

  1. doi request reprint Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 88:237-43. 2012
    ..Therapy-related APL is sensitive to standard therapy with no cases of resistance or relapse seen. The inferior OS of the t-APL was due to induction mortality, possibly reflecting prior therapy...
  2. ncbi request reprint Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 45:1545-9. 2004
    ..021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions...
  3. ncbi request reprint Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    M A Elliott
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 76:1154-62. 2001
    ..While uncommon, TTP and HUS are of considerable clinical importance because of their abrupt onset, fulminant clinical course, and high morbidity and mortality in the absence of early recognition and treatment...
  4. ncbi request reprint Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
    M A Elliott
    Hematology Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1003-8. 2006
    ..Nevertheless, consistent with reported experience of others, overall outcomes remain less than optimal and unpredictable...
  5. ncbi request reprint Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:571-93. 2006
    ..Continued reporting and investigation of specific therapeutic strategies and responses must be encouraged...
  6. ncbi request reprint Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:4172-4. 2007
    ....
  7. doi request reprint Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature
    Mischelle A Elliott
    Department of Internal Medicine Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Haematol 83:365-72. 2009
    ..Prospective studies are urgently needed to define the true efficacy and long-term safety of rituximab...
  8. doi request reprint Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration
    Michelle A Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 85:43-50. 2010
    ..Recognition of cancer-associated microangiopathic hemolytic anemia with thrombocytopenia (CA-MHA) is paramount to avoid inappropriate PE therapy and delays in cancer-specific chemotherapy...
  9. pmc Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
    Michelle Ann Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 95:1788-91. 2010
    ..007) and venous (P=0.02) thromboses were analyzed separately. The current study demonstrates a higher prevalence of venous, as opposed to arterial, events in PMF, post-diagnosis, and clarifies their nature as being mostly provoked...
  10. ncbi request reprint Chronic neutrophilic leukemia: a contemporary review
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 3:210-7. 2004
    ..Continued reporting of all cases of CNL and responses to therapeutic strategies must be encouraged...
  11. ncbi request reprint Thalidomide treatment in myelofibrosis with myeloid metaplasia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 117:288-96. 2002
    ..A lower dose of the drug might be more tolerable without compromising therapeutic value. Patients with PTMM and/or markedly increased circulating CD34+ cell counts might be susceptible to thalidomide-induced thrombocytosis...
  12. ncbi request reprint Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:421-30. 2003
    ..To assess the activity of von Willebrand factor-cleaving protease (vWF-CP) in patients with thrombotic thrombocytopenic purpura (TTP) complicating bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT)...
  13. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  14. doi request reprint A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  15. doi request reprint Thrombotic microangiopathy during peripheral blood stem cell mobilization
    Harris V K Naina
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
    J Clin Apher 24:259-61. 2009
    ..It is possible that GCSF may have directly (activating endothelial cells) or indirectly (activation of underlying autoimmune disorder) contributed to TMA in this patient...
  16. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  17. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  18. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  19. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  20. ncbi request reprint Atypical myeloproliferative disorders: diagnosis and management
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:553-63. 2006
    ....
  21. ncbi request reprint Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1739-43. 2006
    ..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
  22. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  23. ncbi request reprint "Myelodysplasia," myeloneuropathy, and copper deficiency
    Neeraj Kumar
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:943-6. 2005
    ..The hematologic picture can resemble sideroblastic anemia or myelodysplastic syndrome. Hyperzincemia can be an accompanying abnormality even without exogenous zinc ingestion. The reason for the copper deficiency may not be evident...
  24. ncbi request reprint Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera
    Michelle A Elliott
    Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, Rochester, MN 55905, USA E mail
    Curr Hematol Rep 3:344-51. 2004
    ..Additional patient management issues are raised during systemic anticoagulation and surgery. This review summarizes putative pathogenetic mechanisms of bleeding and their management in ET and PV...
  25. doi request reprint Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years
    Pankaj Malhotra
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1724-30. 2008
    ..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
  26. ncbi request reprint MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    Animesh D Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 108:3472-6. 2006
    ..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease...
  27. ncbi request reprint The prognostic significance of trisomy 8 in patients with acute myeloid leukemia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 43:583-6. 2002
    ..The presence of +8 did not appear to adversely affect the outcome of patients with favorable karyotypes...
  28. ncbi request reprint Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:883-9. 2004
    ..To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM)...
  29. ncbi request reprint Thrombocythaemia and pregnancy
    Michelle A Elliott
    Department of Hematology and Internal Medicine, Section of Scientific Publications, Mayo Clinic and Mayo Foundation, Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 16:227-42. 2003
    ..In this communication, we review our own experience as well as that of other investigators on the subject matter and provide management guidelines that are based on best available information...
  30. ncbi request reprint Adverse events after imatinib mesylate therapy
    Michelle A Elliott
    N Engl J Med 346:712-3. 2002
  31. ncbi request reprint Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation
    Rajesh M Prabhu
    Clin Infect Dis 38:1043-5. 2004
  32. ncbi request reprint Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates
    Shireen Sirhan
    Haematologica 90:406-8. 2005
    ..These observations undermine the utility of the PRV-1 assay as a diagnostic test of additional value...